These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 4789106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 3. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P.
    Tidsskr Nor Laegeforen; 1973 Oct 10; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract] [Full Text] [Related]

  • 4. Bensarazid with L-dopa in the treatment of parkinson's disease.
    Van Wieringen A.
    S Afr Med J; 1974 Feb 09; 48(6):206-9. PubMed ID: 4814495
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of Parkinson's disease with levodopa and Ro 4-4602.
    Barbeau A, Gillo-Joffroy L, Mars H.
    Clin Pharmacol Ther; 1971 Feb 09; 12(2):353-9. PubMed ID: 4930866
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E, Hansen E, Melsens S, Parkenberg H, Holm P.
    Acta Neurol Scand Suppl; 1972 Feb 09; 51():115-7. PubMed ID: 4514334
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K, Möller WD.
    Munch Med Wochenschr; 1973 Apr 20; 115(16):711-3. PubMed ID: 4197759
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL, Calne DB, George CF, Vakil SD.
    Clin Pharmacol Ther; 1972 Apr 20; 13(3):400-6. PubMed ID: 5026378
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The treatment of Parkinson's disease with levodopa. Principles. Practical advice. Considerations].
    Sigwald J.
    Nouv Presse Med; 1972 Mar 04; 1(10):679-82. PubMed ID: 5022921
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C, Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Volante F.
    Z Neurol; 1972 Mar 04; 202(4):347-55. PubMed ID: 4117654
    [No Abstract] [Full Text] [Related]

  • 14. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G, Gerdes U, Lehmann K.
    Adv Neurol; 1984 Mar 04; 40():541-7. PubMed ID: 6695634
    [No Abstract] [Full Text] [Related]

  • 15. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.
    Marsden CD, Parkes JD, Rees JE.
    Lancet; 1973 Dec 29; 2(7844):1459-62. PubMed ID: 4129310
    [No Abstract] [Full Text] [Related]

  • 16. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH, Markham CH, Lee JE, Treciokas LJ, Ansel RD.
    Contemp Neurol Ser; 1971 Dec 29; 8():175-201. PubMed ID: 4950056
    [No Abstract] [Full Text] [Related]

  • 17. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W, Danielcyk W, Neumayer E, Riederer P.
    J Neural Transm; 1973 Dec 29; 34(2):133-43. PubMed ID: 4722571
    [No Abstract] [Full Text] [Related]

  • 18. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H.
    Arch Neurol; 1973 Feb 29; 28(2):91-5. PubMed ID: 4683155
    [No Abstract] [Full Text] [Related]

  • 19. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y, Yoshida M, Obayashi T, Ueki A.
    Rinsho Shinkeigaku; 1976 Jul 01; 16(7):511-9. PubMed ID: 986921
    [No Abstract] [Full Text] [Related]

  • 20. [An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
    Pezzoli G, Tesei S, Cossutta E, Ferrante C, Zecchinelli A, Scarlato G.
    Clin Ter; 1988 Apr 30; 125(2):115-20. PubMed ID: 2973932
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.